Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexicaserin - Longboard Pharmaceuticals

Next Previous
Drug Profile

Bexicaserin - Longboard Pharmaceuticals

Alternative Names: AN 352; LP-352

Latest Information Update: 16 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Longboard Pharmaceuticals
  • Class 3-ring heterocyclic compounds; Amides; Antiepileptic drugs; Fluorinated hydrocarbons; Small molecules
  • Mechanism of Action 5-HT2C serotonin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Developmental disabilities

Most Recent Events

  • 16 Oct 2025 Longboard Pharmaceuticals completes a Phase-I pharmacokinetics trials (In volunteers) in USA (PO) prior to May 2025
  • 13 Oct 2025 Bexicaserin - Longboard Pharmaceuticals receives Breakthrough Therapy status for Developmental disabilities in China
  • 25 Sep 2025 Phase-III clinical trials in Developmental disabilities (In adults, In children, In the elderly, In adolescents) in Australia, France, Germany, Italy, Latvia, Serbia, Spain, United Kingdom (PO) (NCT06660394)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top